Innate Biologics has entered into a collaborative research agreement with The Wistar Institute, an international leader in biomedical research.
Innate Biologics, LLC is in the pre-clinical stage of developing novel cosmeceutical and therapeutic approaches for treating and preventing diseases and conditions whose root cause is profound inflammation. These approaches include transdermal applications to treat diverse inflammatory skin conditions that result from trauma, wound healing, reactive dermatitis, and age-related inflammation leading to collagen breakdown and thinning of the skin, including rhytides, commonly known as wrinkles. The therapeutic platform is being developed to treat inflammation associated with auto-immune conditions such as asthma, rheumatoid arthritis, psoriasis, obesity, idiopathic pulmonary fibrosis, ulcerative colitis and Crohn’s disease, and other conditions and syndromes characterized by activation of inflammatory pathways. Innate Biologics, LLC is also developing a therapeutic platform to treat cancer, by attacking the inflammatory response in the local tumor microenvironment.
“We see a large opportunity in both cosmeceutical and therapeutic markets to target the specific molecular pathways that cause inflammation, moving beyond today’s non-targeted approaches. We intend to introduce biologically active proteins to down-regulate the inflammatory response at a molecular level. Innate Biologics, LLC is well along advancing the development of our proprietary approaches and intends to commercialize in cosmeceutical, pharmaceutical and direct-to-consumer marketing channels,” said Peter Mondics, CEO, Innate Biologics, LLC.
For cosmeceutical and therapeutic skin applications, Innate Biologics, LLC is positioned to be a leader in approaches that target skin inflammation by repositioning naturally-occurring, re-engineered bacterial effector proteins prepared in easy-to-apply topical formulations. These proteins are highly specific, potent inhibitors of the NF-kappaB pathways, one of the controlling mechanisms for skin inflammation, which, over time, results in collagen breakdown, photo-aging of the skin, and other associated aging symptoms.
“We were struck by the incredible specificity, potency and selectivity of the platform of bacterial effector proteins and we augmented this naturally occurring platform for NF-kappaB inhibition using proprietary protein engineering approaches developed by Innate Biologics, LLC in collaboration with The Wistar Institute,” said Frank J. Rauscher, III, Ph.D., professor in the Gene Expression & Regulation Program and Caspar Wistar Professor at The Wistar Institute and co-founder of Innate Biologics, LLC.
To accelerate development, Innate Biologics, LLC has secured a world class scientific advisory board with expertise in cosmeceuticals, therapeutics, therapeutic protein delivery and inflammatory pathway signal transduction mechanisms:
- Laura Niedernhofer, M.D., Ph.D., The Scripps Research Institute,
- Albert Baldwin, Ph.D., University of North Carolina School of Medicine, Lineberger Cancer Center
- Paul Robbins, Ph.D., The Scripps Research Institute.
Innate Biologics, LLC has also secured additional expertise, including:
- William R. Strohl, Ph.D., BiStro Consulting, former executive at Johnson & Johnson,
- Duane Morris, retained counsel,
- Nancy R. Phelan, executive advisor, former executive with Bristol-Myers Squibb, Pfizer, Wyeth and Schering-Plough,
- Baker Tilly, retained controller and auditing, and
- Joseph Lamendola, Ph.D, Senior Vice President Life Sciences, Your Encore.
“Innate Biologics is actively seeking partnerships to advance the science and research and to accelerate commercialization,” said Brian J. Riley, president of Innate Biologics, LLC.
About Innate Biologics, LLC
Innate Biologics, LLC is a privately held company targeting, treating and preventing inflammation and is developing a first of its kind recombinant protein platform, which specifically targets intracellular inflammatory signaling pathways. For more information, go to www.InnateBiologics.com.
This press release contains “forward-looking statements” concerning the development of Innate Biologic, LLC’s products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will be commercially successful. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Innate Biologics, LLC undertakes no obligation to update any forward-looking statements for any reason.
About The Wistar Institute
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. Wistar’s business development team is advancing Wistar science and technology development through creative partnerships. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
